Trial Profile
Safety of Pramipexole Monotherapy or Combination Therapy in Chinese Patients With Parkinson¿s Disease: a 12 Week Post Marketing Surveillance
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2013
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 08 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 08 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.